Oregovomab Plus Chemo in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5/GOG-3035)

Ann Surg Oncol. 2023 Mar;30(3):1299-1301. doi: 10.1245/s10434-022-12838-w. Epub 2022 Nov 18.

Authors

Stephanie N Gregory¹, A Leila Sarvestani¹, Carrie E Ryan¹, Martha E Teke¹, Sarfraz R Akmal¹, Jonathan M Hernandez², Sunil Gupta³

Affiliations

¹ Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. jonathan.hernandez@nih.gov.
³ Gynecologic Oncology Group, OncoQuest Pharmaceuticals Inc, Edmonton, Canada.

PMID: 36400892
DOI: 10.1245/s10434-022-12838-w

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Murine-Derived
Carcinoma, Ovarian Epithelial / surgery
Cytoreduction Surgical Procedures*
Female
Humans
Neoadjuvant Therapy
Neoplasm Staging
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / pathology
Ovarian Neoplasms* / surgery

Substances

oregovomab
Antibodies, Monoclonal, Murine-Derived